These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35639570)

  • 1. New analgesics in cancer pain.
    Farrer E; Dickman A
    Curr Opin Support Palliat Care; 2022 Jun; 16(2):60-64. PubMed ID: 35639570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients.
    Jung JY; Chon HJ; Choi YJ; Yeon SE; Choi SY; Lee KH
    Support Care Cancer; 2022 Jul; 30(7):6103-6112. PubMed ID: 35420330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
    Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.
    Matsuoka H; Ishiki H; Iwase S; Koyama A; Kawaguchi T; Kizawa Y; Morita T; Matsuda Y; Miyaji T; Ariyoshi K; Yamaguchi T
    BMJ Open; 2017 Aug; 7(8):e017280. PubMed ID: 28851798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A concept analysis of analgesic nonadherence for cancer pain in a time of opioid crisis.
    Rosa WE; Riegel B; Ulrich CM; Meghani SH
    Nurs Outlook; 2020; 68(1):83-93. PubMed ID: 31443946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Dogan C; Etropolski M; Eerdekens M
    Eur J Pain; 2016 Oct; 20(9):1513-8. PubMed ID: 27062079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine for cancer pain: what is the evidence?
    Jonkman K; van de Donk T; Dahan A
    Curr Opin Support Palliat Care; 2017 Jun; 11(2):88-92. PubMed ID: 28306568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques.
    Mestdagh F; Steyaert A; Lavand'homme P
    Curr Oncol; 2023 Jul; 30(7):6838-6858. PubMed ID: 37504360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action.
    Caputi FF; Nicora M; Simeone R; Candeletti S; Romualdi P
    Minerva Med; 2019 Feb; 110(1):62-78. PubMed ID: 30667206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
    Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.
    Baron R; Eberhart L; Kern KU; Regner S; Rolke R; Simanski C; Tölle T
    Pain Pract; 2017 Jun; 17(5):678-700. PubMed ID: 27611642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic and Refractory Pain: A Systematic Review of Pharmacologic Management in Oncology
.
    Brant JM; Keller L; McLeod K; Yeh C; Eaton LH
    Clin J Oncol Nurs; 2017 Jun; 21(3 Suppl):31-53. PubMed ID: 28524906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
    Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
    Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of pain in cancer patients - recommendations of the Polish Association for the Study of Pain, Polish Society of Palliative Medicine, Polish Society of Oncology, Polish Society of Family Medicine, Polish Society of Anaesthesiology and Intensive Therapy and Association of Polish Surgeons.
    Wordliczek J; Kotlińska-Lemieszek A; Leppert W; Woroń J; Dobrogowski J; Krajnik M; Przeklasa-Muszyńska A; Jassem J; Drobnik J; Wrzosek A; Janecki M; Pyszkowska J; Kocot-Kępska M; Zajączkowska R; Filipczak-Bryniarska I; Boczar K; Jakowicka-Wordliczek J; Malec-Milewska M; Kübler A; Suchorzewski M; Mordarski S; Dziki A; Paśnik K
    Pol Przegl Chir; 2018 Aug; 90(4):55-84. PubMed ID: 30293970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naïve and opioid-tolerant patients: a retrospective study.
    Sazuka S; Koitabashi T
    J Anesth; 2020 Dec; 34(6):834-840. PubMed ID: 32648017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Practical Approach to Using Adjuvant Analgesics in Older Adults.
    Portenoy RK
    J Am Geriatr Soc; 2020 Apr; 68(4):691-698. PubMed ID: 32216151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attitude of Japanese palliative care specialists towards adjuvant analgesics cancer-related neuropathic pain refractory to opioid therapy: a nationwide cross-sectional survey.
    Matsuoka H; Tagami K; Ariyoshi K; Oyamada S; Kizawa Y; Inoue A; Koyama A
    Jpn J Clin Oncol; 2019 May; 49(5):486-490. PubMed ID: 30793161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial.
    Eerdekens MH; Kapanadze S; Koch ED; Kralidis G; Volkers G; Ahmedzai SH; Meissner W
    Eur J Pain; 2019 Mar; 23(3):577-588. PubMed ID: 30365202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Opioids in chronic noncancer pain-are opioids superior to nonopioid analgesics? A systematic review and meta-analysis of efficacy, tolerability and safety in randomized head-to-head comparisons of opioids versus nonopioid analgesics of at least four week's duration].
    Welsch P; Sommer C; Schiltenwolf M; Häuser W
    Schmerz; 2015 Feb; 29(1):85-95. PubMed ID: 25376546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.